Top Markets
#1 Tornado Cash Tornado Cash +6.24%
#2 Story Story +4.55%
#3 UnifAI Network UnifAI Network +4.47%
#4 TENDIES TENDIES +3.72%
#5 Dual Dual +2.92%
#6 Seeker Seeker +2.82%
#7 Cash Cat Cash Cat +2.58%
#8 Figure Heloc Figure Heloc +2.55%
#9 HOME HOME +2.38%
#10 Orochi Network Orochi Network +2.35%
Coin of the day
Tornado Cash Tornado Cash
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Rang in aandelen #16450
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Aandeelprijs
$4.64
Laatst gesynchroniseerd: 2022-09-12
Marktkapitalisatie
$293.43M
Verandering (1 dag)
0.87%
Verandering (1 jaar)
0.00%
Land
US
Handel Adagio Therapeutics, Inc. (ADGI)

Categorie

Healthcare
Winst voor Adagio Therapeutics, Inc. (ADGI)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Adagio Therapeutics, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Adagio Therapeutics, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH